Clinical trials: Severe Ischaemic Stroke
Aortic Valve Disease, Myocardial Infarction
Aspirin Versus Aspirin + ClopidogRel Following Transcatheter Aortic Valve Implantation: the ARTE Trial
The purpose of this study is to compare aspirin + clopidogrel with aspirin alone as antithrombotic treatment following transcatheter aortic valve implantation (TAVI) for the prevention of major ischemic events [myocardial…
- Conditions
- Aortic Valve Disease, Myocardial Infarction, Stroke
- Trial name
- ARTE (NCT01559298)
- Testing
- Aspirin (80 mg/d) + clopidogrel (75 mg/d), Aspirin
- Where
- 2 sites in Canada
- Volunteers
- 178 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Traumatic Brain Injury
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
This study aims to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on brain structure, neurocognitive/functional outcomes, and neuroinflammation after subacute and chronic neurological injury…
- Trial name
- NCT04063215
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences LLC
Ischemic Stroke
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial…
- Trial name
- ARCHIMEDES (NCT06396858)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Colchicine 0.5 MG
- Volunteers
- 4,500 people
- Sponsor
- Brazilian Clinical Research Institute
Acute Ischaemic Stroke
Pragmatic Ischaemic Stroke Thrombectomy Evaluation
Ischaemic strokes (those caused by blockage in an artery in the brain caused by a blood clot) can be treated with very early use of clot-busting (thrombolytic) drugs to attempt to restore the blood supply and limit the damage…
- Trial name
- PISTE (NCT01745692)
- Testing
- Mechanical thrombectomy, Intravenous rtPA
- Where
- United Kingdom
- Volunteers
- 65 people
- Sponsor
- NHS Greater Glasgow and Clyde
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer
Ischemic Stroke
Intensive Drug Therapy for Ischemic Stroke
To observe the safety and efficacy of intensive drug therapy for ischemic stroke patients.Patients with acute stroke caused by intracranial arterial stenosis (stenosis rate ≥70%) were enrolled and accept dual antiplatelet therapy…
- Trial name
- NCT05620615
- Testing
- Intensive Drug Therapy
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shanghai Yueyang Integrated Medicine Hospital
Ischemic Stroke, Acute
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
The aim of this study was to evaluate the efficacy and safety of Minocycline versus placebo in the treatment of patients with moderate to severe acute ischemic stroke.
- Trial name
- EMPHASIS (NCT05836740)
- Testing
- Minocycline hydrochloride capsule
- Where
- 58 sites in China
- Volunteers
- 1,724 people
- Sponsor
- Beijing Tiantan Hospital
Atrial Fibrillation
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation.
- Trial name
- VALIANT-AF-T (NCT06953726)
- Testing
- Apixaban, Rivaroxaban
- Where
- 9 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- VA Office of Research and Development
Hypertension, Stroke
A Cluster-Randomized Controlled Trial
The goal of this study is to learn if an AI-generated personalized health report combined with face-to-face guidance from cardiologists can help rural adults with high blood pressure control their blood pressure better and reduce…
- Conditions
- Hypertension, Stroke, Cardiovascular, Coronary Heart Disease
- Trial name
- NCT07845448
- Testing
- AI-powered personalized health report with cardiologist consultation and prescription optimization, Integrated management (follow-up, education, quality control) without AI report and cardiologist consultation
- Volunteers
- 14,400 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
COVID-19
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Patients with moderate to severe COVID-19 present a very high risk of thromboembolic disease.This multicenter, prospective, randomized, event-driven study evaluates rivaroxaban compared with standard of care with…
- Trial name
- COVID-PREVENT (NCT04416048)
- Testing
- Rivaroxaban, Standard Of Care (SOC)
- Where
- 24 sites in Germany
- Volunteers
- 111 people
- Sponsor
- Charite University, Berlin, Germany
Acute Coronary Syndrome
Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death…
- Trial name
- AEGIS-II (NCT03473223)
- Testing
- Apolipoprotein A-I [human] (apoA-I)
- Where
- 903 sites in United States, Argentina and 47 more
- Volunteers
- 18,226 people
- Sponsor
- CSL Behring
Attention Deficit Disorder With Hyperactivity, Asthma
Study of an Intervention to Improve Problem List Accuracy and Use
The aim of this study is to identify patients with problem list gaps and intervene to correct these gaps by creating clinical decision support interventions that alert providers to likely problem list gaps and offer clinicians…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Asthma, COPD, Breast Cancer
- Trial name
- MAPLE (NCT01105923)
- Testing
- MAPLE
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Brigham and Women's Hospital
Heart Attack, Cardiac Arrest
Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys
Based on limited published epidemiological data, up to an alarming 1 in 50 surgical inpatients die within 30 postoperative days.
- Conditions
- Heart Attack, Cardiac Arrest, Congestive Heart Failure, Atrial Fibrillation
- Trial name
- SATISFY-SOS (NCT02032030)
- Where
- United States
- Volunteers
- 73,952 people
- Sponsor
- Washington University School of Medicine
Stroke, Vascular Severe Brain Injury
Blood Extracellular Vesicles as Predictive Recovery Biomarker After Stroke and Brain Injury
The rehabilitation outcome and recovery, in people after stroke or with vascular severe brain injury(vSBI), are difficult to predict.
- Conditions
- Stroke, Vascular Severe Brain Injury, Rehabilitation
- Trial name
- PRISMA (NCT06871800)
- Testing
- blood withdrawal
- Where
- 3 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Severe Periodontitis, Ischemic Stroke
Effectiveness of Periodontitis Treatment on the Metabolic Activity of Symptomatic Carotid Atherosclerotic Plaque Responsible for Ischemic Stroke
Cardiovascular disease is the world's leading cause of death. Atherothrombosis is a common cause of ischemic stroke. A strong epidemiological link has been established between periodontitis and the risk of stroke.
- Trial name
- PerioStroke (NCT06484036)
- Testing
- periodontal treatment strategy
- Volunteers
- 157 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
- Trial name
- RESTORE (NCT06987643)
- Testing
- Neflamapimod
- Where
- 10 sites in Australia
- Volunteers
- 45 people
- Sponsor
- EIP Pharma Inc
Hemiparesis of the Upper Limb Following Stroke
MyndMove Therapy for Severe Hemiparesis of the Upper Limb Following Stroke
The purpose of this study is to examine the efficacy of MyndMove therapy in the early sub-acute, late sub-acute and chronic post-stroke patients.
- Trial name
- NCT02266836
- Testing
- MyndMove
- Where
- 6 sites in Canada
- Volunteers
- 50 people
- Sponsor
- MyndTec Inc.
Type 2 Diabetes
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
This cohort study was initiated to emulate the design of the SURPASS-CVOT trial using observational analogues of the trial design components in a study based on insurance claims data.
- Trial name
- NCT06779929
- Testing
- Tirzepatide, Dulaglutide, Semaglutide
- Where
- United States
- Volunteers
- 70,000 people
- Sponsor
- Brigham and Women's Hospital
Traumatic Brain Injury, Ischemic Stroke
Shared Decision Making to Improve Goals-of-Care Decisions for Families of Severe Acute Brain Injury Patients
Severe acute brain injury (SABI), including large artery acute ischemic stroke, intracerebral hemorrhage, and severe traumatic brain injury continue to be the leading cause of death and disability in adults in the U.S.
- Conditions
- Traumatic Brain Injury, Ischemic Stroke, Intracerebral Hemorrhage
- Trial name
- NCT03833375
- Testing
- Decision Aid
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Massachusetts, Worcester
Brain Edema, Stroke, Acute
Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction
The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric…
- Trial name
- CHARM (NCT02864953)
- Testing
- BIIB093
- Where
- 250 sites in United States, Australia and 22 more
- Volunteers
- 535 people
- Sponsor
- Remedy Pharmaceuticals, Inc.